Pharmacology
The main active components of St. John's wort are thought to be hypericin and hyperforin. 5 St. John's wort also contains other common plant constituents (e.g., flavonoids and flavonoid derivatives, xanthone derivatives, amentoflavone, biapigenin, volatile oil) that may have antidepressant effects. Although additional research is needed to definitively understand the effects of these components alone and in combination, most available St. John's wort formulations are now standardized to include hypericin (range: 0.1 to 0.4 percent) and hyperforin (range: 2.0 to 4.0 percent) because these constituents have been researched the most extensively.
Studies 6 have suggested that St. John's wort acts via inhibition of the reuptake of serotonin, dopamine, and noradrenaline, along with activation of gamma-aminobutyrate and glutamate receptors. At high dosages, hypericin is a monoamine oxidase inhibitor; however, these effects have not been demonstrated with the consumption of St. John's wort at dosages recommended for the treatment of depression. 7 The absorption and elimination of hypericin extract have been researched in healthy volunteers. 8 After oral ingestion, plasma levels were measurable within two to three hours. A steep cumulative rise in plasma levels was seen during the first three days; however, a more gradual rise continued for several weeks. The elimination half-life was 24 to 48 hours. but one of the 27 clinical studies (n = 2,291) of different hypericum preparations, investigators concluded that St. John's wort was either more effective than placebo or as effective as older pharmaceutical antidepressants in the treatment of mild to moderate depression.
More recently, 13 additional clinical trials have been published, some of which, along with a Cochrane review, are summarized in Table 1 . [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In 10 of these studies, investigators found that St. John's wort was superior to placebo 11, 16, [20] [21] [22] 18 (n = 200), St. John's wort was effective in treating outpatients with major depression. Although the number of patients achieving remission in symptoms of depression was significantly higher with St. John's wort therapy than with placebo (P = .02), overall remission rates were low (14.3 and 4.9 percent, respectively).
The Hypericum Depression Trial Study Group conducted a double-blind, randomized controlled trial 19 (n = 340) in 12 academic and community psychiatric research clinics in the United States. Investigators found that St. John's wort and sertraline did not differ from placebo for major depression outcomes or adverse events. The authors of an earlier study 17 (n = 209) concluded that St. John's wort was equivalent to imipramine in patients with severe depression.
Taken together, the data 10-22 continue to support the overall conclusions of the Cochrane review, 9 as well as other published reviews, 24, 25 that St. John's wort is more effective than placebo and as effective as standard antidepressants for the treatment of mild to moderate depression. 26 reported an overall side-effect rate of 2.4 percent, with no severe side effects and only the expected mild side effects (i.e., gastrointestinal upset, increased anxiety, minor palpitations, photosensitivity, fatigue, restlessness, dry mouth, headache, and increased depression). Transient photosensitivity is generally the most common side effect and occurs more commonly at higher dosages. 27 Use of St. John's wort continues among a substantial number of persons without apparent serious adverse events.
SORT: KEY RECOMMENDATIONS FOR PRACTICE
Because of the possibility of developing serotonin syndrome, use of St. John's wort in 41 suggest that induction of cytochrome (CYP) P450 3A4 activity by St. John's wort may have a substantial impact on the effectiveness of pharmaceutical agents because at least one half of all marketed medications are metabolized via this pathway.
Given the induction of CYP 3A4, concurrent use of St. John's wort may reduce the effectiveness of oral contraceptives. In a study 35 of 12 healthy premenopausal women who received an oral contraceptive along with 900 mg of St. John's wort daily in three divided doses, researchers noted a shorter estrogen half-life and increased breakthrough bleeding. Women using oral contraceptives should be counseled regarding possible breakthrough bleeding and might consider a barrier method of contraception when taking St. John's wort. 35 Additional study is needed to establish if and how St. John's wort interacts with specific pharmaceutical agents. Experience to date suggests few clinically significant interactions. Until the results of ongoing studies on this matter have been published, the medications listed in Table 2 29-40 should be considered to have potential interactions and should be monitored when used concurrently with St. John's wort. Family physicians should query all patients about the use of St. John's wort and other herbal agents.
Dosage
Findings suggest that 900 mg of St. John's wort (450 mg two times daily or 300 mg three times daily) is needed to reduce symptoms of depression. 8, 10, 17 Because plasma levels continue to show a gradual rise over 
